Latest Views & News

Optibiotix – Nizo deal: valuation crackers, buy

By Tom Winnifrith | Saturday 20 September 2014


Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


OptiBiotix Health (OPTI), the former Ducat Ventures,  has announced it is contracting Netherlands-based Nizo Food Research BV to undertake pre-clinical claims support for three cholesterol-lowering ‘Lactobacillus’ strains that OptiBiotix has developed.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Thursday »

HAYD

Haydale - Full Year Results Disaster

 

SAGA

The ongoing saga of woe at Saga

 

Quiz

The ShareProphets Sunday Pub Quiz #160

 

VCP

Gyrations at Victoria Carpets

 

MADE

GOTCHA: Made.com admits it is fucked

 

Bull

Stuff happens but we are not stuffed

 

Quiz

The ShareProphets Sunday Pub Quiz #159

 

OCDO

Challenges continue at Ocado

 

ICON

Iconic Labs – back from the dead?

 

PUR

Pure Gold – Pure Ramping!

Sunday »

Quiz

The ShareProphets Sunday Pub Quiz #158